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Lowered B-Type Natriuretic Peptide in Response
to Levosimendan or Dobutamine Treatment
Is Associated With Improved Survival in Patients
With Severe Acutely Decompensated Heart Failure
Alain Cohen-Solal, MD, PHD,* Damien Logeart, MD,* Bidan Huang, PHD,† Danlin Cai, PHD,†
Markku S. Nieminen, MD,‡ Alexandre Mebazaa, MD, PHD*
Paris, France; Abbott Park, Illinois; and Helsinki, Finland
Objectives The purpose of this analysis was to examine whether decreases in B-type natriuretic peptide (BNP) levels during
the first few days of hospitalization were associated with greater survival in patients with severe acutely decom-
pensated heart failure (ADHF).
Background BNP level is a prognostic marker for all-cause mortality (ACM) in ADHF; whether early BNP changes can also
help predict outcome in patients who need inotropes for treatment of severe ADHF is not known.
Methods We retrospectively assessed the association between changes in BNP levels and ACM in patients from the
SURVIVE (Survival of Patients with Acute Heart Failure in Need of Intravenous Inotropic Support) trial—a ran-
domized, controlled trial comparing levosimendan to dobutamine treatment in patients hospitalized with ADHF.
BNP levels were measured at baseline and at days 1, 3, and 5. A patient was classified as a “responder” if the
follow-up BNP level was 30% lower than baseline BNP. The relationship between early BNP response and sub-
sequent ACM over short- (31-day) and long-term (180-day) intervals was evaluated.
Results Of 1,327 SURVIVE patients, this analysis included 1,038 who had BNP samples at both baseline and day 5. Re-
sponders at days 1, 3, and 5 had lower ACM than did nonresponders (p  0.001), with day-5 levels showing su-
perior discriminating value. Short-term ACM (31-day) risk reduction was 67% in day-5 BNP responders compared
with nonresponders, whereas long-term (180-day) ACM risk reduction was 47%.
Conclusions Patients with lowered BNP on treatment for ADHF had reduced mortality risks (31- and 180-day) compared to
those with little or no BNP decrease. These results suggest that early lowering of BNP predicts both short- and long-
term mortality risks. BNP reduction may therefore serve as a suitable prognostic marker of ACM. (Survival of Patients
With Acute Heart Failure in Need of Intravenous Inotropic Support [SURVIVE]; NCT00348504) (J Am Coll Cardiol
2009;53:2343–8) © 2009 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.02.058i
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ratriuretic peptides (B-type natriuretic peptide [BNP] or
-terminal pro–B-type natriuretic peptide [NT-proBNP])
ave rapidly gained popularity as biomarkers of diagnostic
nd prognostic value in patients with acute and chronic
eart failure (1–4). Previous studies found that discharge
NP values were strong predictors of subsequent outcomes
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Manuscript received September 2, 2008; revised manuscript received January 20,
009, accepted February 3, 2009.n patients admitted for acute decompensation of heart
ailure (ADHF) (5). However, it is not known whether this
ssociation holds true for ADHF patients who have severe
emodynamic compromise and need inotrope therapy.
oreover, since such patients have high in-hospital mor-
ality rates, particularly within the first few days of admis-
ion, BNP changes during the early treatment interval may
elp assess in-hospital responses to therapy and predict
utcomes as well.
See page 2349
Our current report describes a retrospective analysis of
esults from patients in the SURVIVE (Survival of Patients
ith Acute Heart Failure in Need of Intravenous Inotropic
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BNP and Prognosis in Acutely Decompensated HF June 23, 2009:2343–8Support) trial. SURVIVE is the
largest randomized, double-blind
study to date assessing the effect of
treatment on short- (1-month)
and long-term (6-month) mortal-
ity in patients who were hospi-
talized with severe ADHF (6).
We sought to determine whether
early changes in plasma BNP
levels—within the first 5 days of
hospitalization in the acute care
ward—could predict short- and
long-term mortality for severe
ADHF patients.
ethods
URVIVE was a randomized, multicenter, international,
ouble-blind, double-dummy, parallel group, active-controlled
rial of levosimendan versus dobutamine in patients with severe
DHF (6). The primary end point was all-cause mortality
ACM) at 180 days. Change in BNP concentration from
nitiation of study drug to 24 h was a secondary end point, with
NP levels at 72 and 120 h as additional efficacy parameters.
valuation of mortality at days 1, 5, and 14, in addition to
re-specified analyses at days 31 and 180 were included as post
oc analyses. Patients enrolled in the SURVIVE trial had a left
entricular ejection fraction30% within the prior 12 months
nd were in need of inotropic support, defined as an insufficient
esponse to intravenous diuretics and/or vasodilators with at
east 1 of the following: 1) oliguria; 2) dyspnea at rest or on
echanical ventilation; or 3) pulmonary-capillary wedge pres-
ure 18 mm Hg or cardiac index 2.2 l/min. Exclusion
riteria were a systolic blood pressure 85 mm Hg; heart rate
130 beats/min for 5 min; concurrent inotropic agents,
xcept digitalis or dopamine (2g/kg/min); serum creatinine
5.0 mg/dl or on dialysis; significant hepatic impairment
investigator discretion); or severe obstruction of ventricular
utflow tracts.
Patients received either levosimendan or dobutamine
s an intravenous infusion. Levosimendan was adminis-
ered for 24 h, first as a loading dose of 12 g/kg over 10
in, followed by a continuous infusion at 0.1 g/kg/min
or the next 50 min and 0.2 g/kg/min for the remaining
3 h, as tolerated. Dobutamine was administered as long
s clinically indicated (minimally 24 h) with a beginning
nfusion rate of 5 g/kg/min and upward titration to a
aximum of 40 g/kg/min, as tolerated, to achieve
linical goals.
NPmethodology and analyses. Plasma samples for BNP
ssay were collected at baseline, 24 h, 3 days, and 5 days
fter the start of the study drug infusion. BNP values
pg/ml) were determined using the AxSYM BNP immu-
oassay (iBNP, Abbott Diagnostics, Abbott Park, Illinois).
ithin-run and total percent coefficient of variation for this
Abbreviations
and Acronyms
ACEI  angiotensin-
converting enzyme inhibitor
ACM  all-cause mortality
ADHF  acute
decompensation of heart
failure
ANOVA  analysis of
variance
BNP  B-type natriuretic
peptide
ROC  receiver-operator
characteristicest are between 6.0% and 8.5%. Change from baseline cNP concentration included only data from patients with
NP assay results available at both baseline and the specific
ample time point evaluated.
tatistical analyses. To differentiate short-term variations
n BNP levels from clinically meaningful changes (7–9), we
xamined the definition of responder as a patient with a
ecrease from baseline BNP value 30% at a given sample
ime point (day 1, 3, or 5) post hoc. This cutoff of 30%
ecrease in BNP to define and differentiate responders from
onresponders was tested by receiver-operator characteristic
ROC) analysis of data and indeed optimally separated
atients with low and high mortality rates. The Cox
roportional hazards model analysis was performed for time
o ACM by 31 and 180 days with BNP status as the factor.
NP status by treatment interaction was examined in the
odel prior to fitting the above model and was found not
tatistically significant.
As previous studies have suggested that absolute BNP
alue at discharge also has high prognostic value (5,10), we
epeated the analysis defining responders as those with BNP
owered below the cutoff level of 800 pg/ml at day 5; this
utoff was previously found to be associated at discharge
ith a 75% rate of death or rehospitalization (5). Similar
nadjusted Cox proportional hazards model analysis was
lso performed for time to ACM by 31 and 180 days with
he factor for BNP response status based on day 5 absolute
NP value.
We also assessed the relationship between BNP response
tatus and ACM at days 31 and 180 while controlling for
mportant baseline characteristics (systolic blood pressure,
iastolic blood pressure, laboratory creatinine value, BNP,
istory of heart failure, angiotensin-converting enzyme
nhibitor [ACEI] use, and beta-blocker use) and treatment
llocation. To do so, we performed additional post hoc
nalyses using a Cox proportional hazards model for time to
CM and logistic regression model for mortality (yes/no)
sing BNP response status and these baseline covariates as
he dependent variables in the model. The ROC curves
rom a logistic regression model were computed to assess
he fit of the model.
Survival in responders and nonresponders was also
nalyzed using the Kaplan-Meier cumulative mortality
ethod. Survival curves were compared using the log-
ank test. The comparability of demographic character-
stics between the day-5 BNP responders and nonre-
ponders was assessed using a chi-square test for
ategorical variables and analysis of variance (ANOVA)
ith response status as a factor for continuous variables.
he Kruskal-Wallis nonparametric test was used to
valuate differences between responders and nonre-
ponders for baseline BNP to address the non-normality
f the data. The Fisher exact test was used to compare
esponder and nonresponder groups for incidences of
dverse events. SAS version 8.20 (SAS Institute Inc.,
ary, North Carolina) was used. A value of p  0.05 wasonsidered statistically significant.
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June 23, 2009:2343–8 BNP and Prognosis in Acutely Decompensated HFesults
he overall mortality rates in the SURVIVE population
f 1,327 ADHF patients were 13% at 31 days and 27% at
months (6). Of 1,327 SURVIVE patients, our analyses
ncluded 1,038 patients who had BNP samples taken at
oth baseline and day 5. Of the 1,327 patients, 69 (5.2%)
ied prior to day 5; 217 did not have BNP samples at
oth baseline and day 5; and 3 had BNP sample reading
rrors of value zero. On day 1, 17 (1.3%) subjects died
rior to BNP sampling, and 74 subjects did not have
NP samples at both baseline and day 1.
ssessment of BNP change versus mortality rates. The
OC analyses of cutoffs between5% and40% showed that
cutoff of30% BNP decrease had the highest area under the
urve value (0.786), and this cutoff value was thus selected to
efine and differentiate responders from nonresponders. Mortal-
ty rates at 31 and 180 days according to various cutoffs of BNP
ecrease at day 5 are displayed in Figure 1. The threshold of
0% change in BNP optimally separated patients with low and
igh mortality rates. Conversely, patients having an increase in
NP between baseline and day 5 had a 31-day mortality rate
or more times higher than patients with a decrease in BNP
f 30% or more.
BNP, % c
0
%
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ta
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Figure 1 Mortality Rates According to BNP Changes
Mortality rates at 31 and 180 days according to increases (0%) and decreases
in B-type natriuretic peptide (BNP) by 15%, 30%, 45%, and 60% between baseline
ortality Rates for Nonresponders Versus Responders at 31 and 1
Table 1 Mortality Rates for Nonresponders Versus Responders
31-Day Mortality
Nonresponder Responder Hazard Ratio† (95% CI)
Day 1 (n  1,236) 15.0% 8.9% 0.568 (0.408–0.792)
Day 3 (n  1,104) 12.6% 6.2% 0.475 (0.316–0.714)
Day 5 (n  1,038) 13.1% 4.6% 0.331 (0.208–0.525)
Responders were defined as individuals having a day-5 B-type natriuretic peptide (BNP) level 
roportional hazards model with BNP response status, treatment allocation, and baseline covariates as t
CI  confidence interval.redictive value of BNP changes over early intervals. At
arly time points (days 1, 3, and 5), better likelihood for
urvival was predicted by 30% lowering of plasma BNP
rom baseline level, that is, responder status; however,
eing a responder at day 5 provided numerically lower
azard ratios at both 31- and 180-day mortality than did
eing a responder at day 1 or 3 (Table 1). Based on these
esults, we used BNP decrease from baseline to day 5 as
he preferred time interval for outcome prediction. With
he Cox proportional hazards regression model, respond-
rs at day 5 had a 67% risk reduction in 31-day mortality
ompared with nonresponders (p  0.001). For 180-day
ortality, the risk reduction was 47% (p  0.001).
ignificant differences were confirmed by Kaplan-Meier
urvival curves (log-rank test p  0.0001) (Fig. 2).
NP change versus absolute BNP value in prediction of
utcome. In accord with the median BNP value at day 5 of
68 pg/ml and previous experience, an absolute BNP cutoff
alue 800 pg/ml (at day 5) was tested for prognostic
ignificance (Table 2). BNP values below 800 pg/ml at day
had short- and long-term prognostic values similar to
hose observed with the 30% decrease from baseline BNP
t day 5, based on comparison of ROC values from the
ge from baseline
-31 to -45 -46 to -60 -60>
Day 31
Day 180
19/139
7/139 6/127
28/127
51/283
12/283
y 5.
ays*
and 180 Days*
180-Day Mortality
Value Nonresponder Responder Hazard Ratio† (95% CI) p Value
.001 30.3% 22.5% 0.692 (0.555–0.862) 0.001
.001 29.4% 19.5% 0.615 (0.482–0.784) 0.001
.001 30.3% 17.9% 0.529 (0.410–0.683) 0.001
ower than baseline BNP. †Adjusted hazard ratio of responders versus nonresponders from Coxhan
 -30
27/96
and da80 D
at 31
p
0
0
0
30% l
he dependent variables in the model.
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BNP and Prognosis in Acutely Decompensated HF June 23, 2009:2343–8ogistic models or with 2 log likelihood values from the
ox proportional hazards model.
aseline characteristics affecting BNP response. There
as no difference in the baseline values in the groups of
esponders and nonresponders regarding age, sex, and rates
f hypertension (Table 3). There were lower proportions of
eople with previous history of heart failure (p  0.05) or
yocardial infarction (p  0.001) among nonresponders
ut a higher proportion of people with diabetes (p 0.007).
here was also no difference at baseline regarding the rate of
rescription of ACEIs, beta-blockers, furosemide, spirono-
actone, or lipid-lowering agents. However, BNP respond-
rs more often received levosimendan than dobutamine
reatment (63% levosimendan vs. 37% dobutamine; p 0.001).
aseline plasma BNP was higher in responders than in
onresponders. Significant but modest differences were
bserved at baseline regarding blood pressure and sodium
nd potassium levels. There were no differences in heart
ate, plasma creatinine, or transaminase levels.
djusted analyses. To assess whether the BNP response
tatus and 31-day mortality rate were affected by other
actors, we assessed baseline parameters, treatment alloca-
ions, and BNP responses. A multivariate analysis examined
hether the prognostic value of BNP response at day 5 was
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Figure 2 Kaplan-Meier Survival Curves
Kaplan-Meier survival curves (180 days) are shown according to decreases in B-typ
baseline and day-5 nonresponders (30% BNP decrease from baseline) and respo
tatistical Analysis: Prediction of Mortality by Percent Change in B
Table 2 Statistical Analysis: Prediction of Mortality by Percent
Mortality Time
Points
Responders, Defined as >30% Lowering From Baseline to
(n  549/1,038)
Mortality Rates
R/NR
Adjusted Hazard Ratio*
(p Value)
Mortality
(RO
31-day 4.6%/13.1% 0.33 (0.0001) 0.7
180-day 17.9%/30.3% 0.54 (0.0001) 0.7
esults are reported as percentage all-cause mortality, adjusted hazard ratios, and model fitting. *
ith B-type natriuretic peptide (BNP) response status, treatment allocation, and baseline covariates as the d
rom logistic regression analysis.etained after stratifying by treatment allocation; baseline
lood pressure; plasma creatinine; BNP value; or previous
istory of chronic heart failure and treatment with ACEI or
eta-blockers. Only day-5 BNP response (chi-square: 17.6,
 0.0001), baseline BNP (chi-square: 12.6, p  0.0004),
lasma creatinine (chi-square: 9.7, p  0.0018), ACEI
reatment (chi-square: 7.8, p  0.005), and beta-blocker
reatment (chi-square: 5.0, p  0.03) were significantly
ssociated with outcome at 31 days by Cox proportional
azards model analysis.
dverse events. We also investigated whether BNP re-
ponses were associated with any greater rate of adverse events
uring the entire study period, related to important and/or
apid hemodynamic changes. There was no significant differ-
nce in the rates of acute coronary syndrome, hypotension,
enal failure, or acute myocardial infarction between responders
nd nonresponders during the 180 days of the study (Table 4).
ccurrence of cardiogenic shock, cardiac failure, and ventric-
lar tachycardia was significantly less in the responder group
Table 4). There was a significant difference between respond-
rs and nonresponders regarding overall serious adverse events;
2% (119 of 549) of responders and 32% (158 of 489) of
onresponders had events (Table 4).
y Drug Infusion
0 120 180150
Non-Responder
Responder
riuretic peptide (BNP) between
(30% BNP decrease from baseline).
t Day 5 Versus Absolute BNP Level
nge in BNP at Day 5 Versus Absolute BNP Level
5 Responders, Defined as BNP <800 pg/ml at Day 5
(n  554/1,079)
l Fit Mortality Rates
R/NR
Adjusted Hazard Ratio*
(p Value)
Mortality Model Fit
(ROC)†
3.1%/14.9% 0.31 (0.0001) 0.781
15.0%/33.0% 0.59 (0.0009) 0.700
d hazard ratio of responders (R) versus nonresponders (NR) from Cox proportional hazards modeltud
9
e nat
ndersNP a
Cha
Day
Mode
C)†
86
10
Adjuste
ependent variables in themodel. †The area under the receiver-operator characteristic (ROC) curve
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June 23, 2009:2343–8 BNP and Prognosis in Acutely Decompensated HFiscussion
ur current analyses of the SURVIVE trial showed that a
ecrease in BNP of 30% or more during the first 5 days of
n-hospital management of patients with ADHF was pos-
tively associated with improved survival at 31 and 180 days,
egardless of the treatment group allocation. In SURVIVE
atients, we observed that an early decrease in BNP level,
hether assessed at day 1, 3, or 5, was associated with lower
ortality over time. In particular, a BNP response (either
efined by 30% lowering from baseline or by an absolute
alue800 pg/ml) at day 5 appeared to best predict survival
t days 31 or 180. Not surprisingly, the decrease in BNP at
aseline Characteristics of Patients Whoer Nonresponder Versus Responders* at Day 5
Table 3 Baseline Characteristics of Patients WhoWere Nonresponders Versus Responders* at Day 5
Nonresponders
at Day 5
Responders
at Day 5 p Value
n 489 549
Age (yrs) 66 12 67 12 0.642
Male 71 69 0.412
Caucasian 97 97 0.438
Weight (kg) 79 17 79 18 0.852
Chronic heart failure 87 91 0.05
Myocardial infarction 72 83 0.001
Hypertension 63 64 0.700
Diabetes 36 28 0.007
ICD 4 4 0.974
Pacemaker 12 9 0.213
SBP (mm Hg) 114 18 120 19 0.001
DBP (mm Hg) 70 11 73 12 0.001
Heart rate (beats/min) 84 17 83 18 0.269
ALT (U/l) 90 350 71 223 0.328
AST (U/l) 101 460 69215 0.157
Alkaline phosphatases (U/l) 118 90 105 55 0.007
Creatinine (mol/l) 123 54 120 62 0.348
Glucose (mol/l) 7.9 3.3 7.6 3.2 0.078
Potassium (mol/l) 4.3 0.6 4.4 0.6 0.034
Sodium (mol/l) 137 5 138 5 0.001
BNP (pg/ml)
Mean  SD 1,462 1,433 1,842 1,700 0.001
Median (Q1–Q3) 1,130 (524–1,911) 1,407 (739–2,360)
Furosemide 91 93 0.373
ACEI 70 73 0.211
ARB 6 4 0.146
Antithrombotic agents 86 87 0.458
Beta-blockers 51 55 0.236
Digitalis 39 41 0.409
Dopamine 7 5 0.100
Lipid-lowering drugs 25 22 0.238
Spironolactone 54 59 0.165
Vasodilators 63 68 0.138
Levosimendan, % treatment 37 63 0.001
esults are given as absolute values for numerical data and as percentages for categorical
ariables. *Responders were defined as individuals having day-5 B-type natriuretic peptide (BNP)
evel 30% lower than baseline BNP.
ACEI  angiotensin-converting enzyme inhibitor; ALT  alanine aminotransferase; ARB 
ngiotensin receptor blocker; AST  aspartate aminotransaminase; DBP  diastolic blood
ressure; ICD  implantable cardiac defibrillator; Q  quartile; SBP  systolic blood pressure.ay 5 better predicted mortality at day 31 than at day 180;any aspects of care after the initial month of therapy can
nfluence outcome beyond the first weeks, for example,
nitiation of beta-blocker therapy, ACEI dose increase,
evascularization, and patient education. The BNP–survival
elationship was independent of other factors known to
ffect prognosis, such as baseline plasma BNP or creatinine
evels, blood pressure, or history of heart failure and certain
eart failure treatment medications at entry. Most impor-
antly, although more levosimendan patients than dobut-
mine patients belonged to the day-5 responders, the
NP–survival relationship was consistent regardless of
hether patients were allocated for treatment with levosi-
endan or dobutamine. Notably, an increase in BNP
uring the first 5 days was associated with a much poorer
utcome than a decrease in BNP with therapy.
Our study results are consistent with findings of another
tudy group. Kazanegra et al. (11) were among the first to
emonstrate a close relationship between a decrease in
ulmonary wedge pressure and decreased plasma BNP
uring in-hospital treatment of patients with ADHF; this
bservation was thought to reflect the important treatment
oal of achieving a favorable cardiac pre-load in this
opulation, usually by decreasing left ventricular filling
ressures by use of diuretics, nitrates, phosphodiesterase
nhibitors, or nesiritide. Subsequent studies, however, were
ot consistent for this correlation between BNP and pul-
onary wedge pressure (12–15). Our findings are also
onsistent with prior results in ambulatory patients with
ongestive heart failure, which showed that a strategy
imed at decreasing BNP levels was more effective for
redicting prognosis than was a traditional strategy based
n clinical judgment (16,17).
Previous studies also reported that natriuretic peptide
BNP or NT-proBNP) decreases (from baseline to dis-
harge) or low absolute BNP values at discharge (between 7
nd 15 days) were associated with better outcomes in
ingle-center study populations of heart failure patients
ho had moderately compromised hemodynamic status
5,10,18,19). Our findings in SURVIVE patients extended
uch observations to a larger multicenter, multinational
opulation of patients with heart failure so severe that the
atients needed intravenous inotrope therapy.
ates of Reported Seriousdv rse Events (in Percentages) inonre pond rs and Resp nders (Ent re Study Period)
Table 4
Rates of Reported Serious
Adverse Events (in Percentages) in
Nonresponders and Responders (Entire Study Period)
Nonresponders
(n  489)
Responders
(n  549) p Value
Acute coronary syndrome 0.2 0.5 0.627
Shock 2.9 0.9 0.021
Acute myocardial infarction 0.2 0.4 1.000
Ventricular tachycardia 4.3 0.9 0.001
Renal failure 0.8 0.9 1.000
Hypotension 1.4 1.1 0.781Cardiac failure 11.5 6.9 0.013
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BNP and Prognosis in Acutely Decompensated HF June 23, 2009:2343–8Prompt treatment is vital to rapid correction of compro-
ised hemodynamic status in patients hospitalized with
DHF. A major concern, however, is that overly aggressive
trategies might result in adverse events such as treatment-
elated hypotension, renal failure, or arrhythmias. Notably,
URVIVE study treatments marked by BNP decreases
30% from baseline to day 5 were not associated with
ncreased frequencies of these side effects.
tudy limitations. Our results show that the BNP decrease
n the first days of treatment has a similar prognostic value
o a lower absolute value of BNP at day 5. However, the
igh prognostic value of day-5 BNP changes (or lower
bsolute levels of BNP) applies only to patients still alive at
his time point. In the SURVIVE trial, 69 patients (5.2%,
epresenting 40% of 31-day mortality) died before day 5.
hese early deaths could not have been predicted by the
ay-5 BNP response. In this regard, the day-1 BNP
esponse (hazard ratio: 0.57, p  0.0001), although less
redictive than the day-5 response, may be of value for the
linicians in charge of patients in acute-care settings.
Our findings thus suggest that BNP response (lower
evels) with treatment can predict ACM prognosis; how-
ver, these findings and the prognostic value of day-1 or
ay-5 BNP response with regard to treatments should be
ested in prospective studies of hospitalized patients receiv-
ng treatment for ADHF.
onclusions
aken together, our findings and those of others support the
oncept that BNP changes during the first 5 days of hospital-
zation have a very high prognostic value in patients with heart
ailure. In our study of SURVIVE data, BNP lowering by
ore than 30% from baseline during the first 5 days predicted
oth 31- and 180-day mortality; BNP change by day 5 was a
etter predictor than was change on the first day. Day-1 BNP
hange, however, also has high value by providing early
rognostic information. Such early and reliable prediction
nformation offers the advantage of achieving early optimiza-
ion of treatment. Consistent with our current findings in
atients hospitalized with ADHF, we hypothesize that survival
an be improved when the in-hospital treatment algorithm is
imed at decreasing BNP more than 30% or lowering BNP to
800 pg/ml within 5 days of admission; however, this strategy
equires further study to determine whether it remains valid
hen specific treatments are used.
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